Cargando…

Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia

Background: The programmed cell death ligand 1/programmed cell death receptor 1 (PD-L1/PD-1) Immune Checkpoint is an important modulator of the immune response. Overexpression of the receptor and its ligands is involved in immunosuppression and the failure of an immune response against tumor cells....

Descripción completa

Detalles Bibliográficos
Autores principales:	Ries, Jutta, Agaimy, Abbas, Wehrhan, Falk, Baran, Christoph, Bolze, Stella, Danzer, Eva, Frey, Silke, Jantsch, Jonathan, Möst, Tobias, Büttner-Herold, Maike, Wickenhauser, Claudia, Kesting, Marco, Weber, Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7920045/ https://www.ncbi.nlm.nih.gov/pubmed/33669300 http://dx.doi.org/10.3390/biomedicines9020194

Ejemplares similares

Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile
por: Weber, Manuel, et al.
Publicado: (2019)

Malignant transformation of oral leukoplakia is associated with macrophage polarization
por: Weber, Manuel, et al.
Publicado: (2020)

PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma
por: Weber, Manuel, et al.
Publicado: (2017)

Beyond PD-L1—Identification of Further Potential Therapeutic Targets in Oral Cancer
por: Weber, Manuel, et al.
Publicado: (2022)

Zoledronate Causes a Systemic Shift of Macrophage Polarization towards M1 In Vivo
por: Weber, Manuel, et al.
Publicado: (2021)

Galectin 3 expression in regional lymph nodes and lymph node metastases of oral squamous cell carcinomas
por: Wehrhan, Falk, et al.
Publicado: (2018)

PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma
por: Göbel, Holger H., et al.
Publicado: (2022)

The Special Developmental Biology of Craniofacial Tissues Enables the Understanding of Oral and Maxillofacial Physiology and Diseases
por: Weber, Manuel, et al.
Publicado: (2021)

Galectin 3 expression in primary oral squamous cell carcinomas
por: Weber, Manuel, et al.
Publicado: (2017)

Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: a comparison with osteoradionecrosis and osteomyelitis
por: Wehrhan, Falk, et al.
Publicado: (2019)

Craniofacial Osteosarcoma—Pilot Study on the Expression of Osteobiologic Characteristics and Hypothesis on Metastasis
por: Weber, Manuel, et al.
Publicado: (2020)

Increased malignancy of oral squamous cell carcinomas (oscc) is associated with macrophage polarization in regional lymph nodes – an immunohistochemical study
por: Wehrhan, Falk, et al.
Publicado: (2014)

Postoperative Changes in Systemic Immune Tolerance Following Major Oncologic versus Minor Maxillofacial Surgery
por: Trumet, Leah, et al.
Publicado: (2023)

Alterations in macrophage polarization in the craniofacial and extracranial skeleton after zoledronate application and surgical interventions – an in vivo experiment
por: Struckmeier, Ann-Kristin, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Evaluation of the clinical molecule anti-human-PD-L1/IL-15 KD033 in the human-PD-1/PD-L1-expressing murine model demonstrates PD-L1 targeting of IL-15 in vivo
por: Martomo, Stella A., et al.
Publicado: (2022)

Expression of Msx-1 is suppressed in bisphosphonate associated osteonecrosis related jaw tissue-etiopathology considerations respecting jaw developmental biology-related unique features
por: Wehrhan, Falk, et al.
Publicado: (2010)

Basis of PD1/PD-L1 Therapies
por: Seliger, Barbara
Publicado: (2019)

Therapeutic PD-L1 antibodies are more effective than PD-1 antibodies in blocking PD-1/PD-L1 signaling
por: De Sousa Linhares, Annika, et al.
Publicado: (2019)

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates
por: Majer, Christiane, et al.
Publicado: (2023)

PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
por: Stein, Alexander, et al.
Publicado: (2021)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
por: Janning, Melanie, et al.
Publicado: (2019)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
por: Long, Yiru, et al.
Publicado: (2022)

PD-1/PD-L1 Inhibitors in Cervical Cancer
por: Liu, Yuncong, et al.
Publicado: (2019)

PD-L1/PD-1 Axis in Glioblastoma Multiforme
por: Litak, Jakub, et al.
Publicado: (2019)

A snapshot of the PD-1/PD-L1 pathway
por: Ghosh, Chinmoy, et al.
Publicado: (2021)

The PD-1:PD-L1 axis in Inflammatory Arthritis
por: Canavan, Mary, et al.
Publicado: (2021)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

PD-1/PD-L1 axis in organ fibrosis
por: Zhao, Youliang, et al.
Publicado: (2023)

Progress of research on PD-1/PD-L1 in leukemia
por: Cao, Huizhen, et al.
Publicado: (2023)

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis
por: Böttcher, Martin, et al.
Publicado: (2021)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Programmed Death 1 (PD-1) and PD-1 Ligand (PD-L1) Expression in Chronic Apical Periodontitis
por: Delgado, Ronan Jacques Rezende, et al.
Publicado: (2019)

Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response
por: Diggs, Laurence P., et al.
Publicado: (2017)

In vitro Interactions of Chicken Programmed Cell Death 1 (PD-1) and PD-1 Ligand-1 (PD-L1)
por: Reddy, Vishwanatha R. A. P., et al.
Publicado: (2019)

Standardisierte histomorphologische Aufarbeitung von Peritonealbiopsien im Rahmen des Deutschen Peritonealbiopsieregisters (GRIP, German Registry In PD)
por: Pfister, Frederick, et al.
Publicado: (2020)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Increase of cells expressing PD‐1 and PD‐L1 and enhancement of IFN‐γ production via PD‐1/PD‐L1 blockade in bovine mycoplasmosis
por: Goto, Shinya, et al.
Publicado: (2017)

Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
por: Shen, Xian, et al.
Publicado: (2018)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rl2tl3rgfq864jr8pt2fj31os7